Possible survival benefit of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin combination therapy (HD-MVAC) over conventional MVAC in metastatic urothelial carcinoma patients

Possible survival benefit of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin combination therapy (HD-MVAC) over conventional MVAC in metastatic urothelial carcinoma patients

Eight patients with metastatic urothelial carcinoma received high-dose (HD)-MVAC therapy, which consisted of methotrexate (30 mg/m2) on day 1, vinblastine (3 mg/m2) on day 2, doxorubicin (30 mg/m2) on day 2 and cisplatin (70 mg/m2) on day 2 (14-day cycle). Patients were treated with granulocyte colo...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Hinyokika kiyo. Acta urologica Japonica. - 1962. - 53(2007), 9 vom: 12. Sept., Seite 613-8
1. Verfasser: Inoue, Takamitsu (VerfasserIn)
Weitere Verfasser: Obara, Takashi, Saito, Mitsuru, Kumazawa, Teruaki, Yuasa, Takeshi, Matuura, Shinobu, Tsuchiya, Norihiko, Satoh, Shigeru, Habuchi, Tomonori
Format: Aufsatz
Sprache:English
Veröffentlicht: 2007
Zugriff auf das übergeordnete Werk:Hinyokika kiyo. Acta urologica Japonica
Schlagworte:Comparative Study Journal Article Granulocyte Colony-Stimulating Factor 143011-72-7 Vinblastine 5V9KLZ54CY Doxorubicin 80168379AG Cisplatin Q20Q21Q62J mehr... Methotrexate YL5FZ2Y5U1